A Phase 2 interventional study of STP938 in Essential Thrombocythaemia, sponsored by Step Pharma, SAS. Recruiting at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by Step Pharma, SAS · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Thrombocythemia, Essential with a site in France — 7 open to participants now, 12 under way, 5 of them phase 3. Thrombocythemia, Essential · France.
Among the 37 studies in Thrombocythemia, Essential with a site in France, this one is the 23rd largest by planned enrollment of the 27 interventional ones that give a count, is the only one that started in 2025, is one of 5 in phase 2, reaches primary completion later than 9 of the 11 other live ones, and was the 35th registered.
229 studies on the registry are indexed under Thrombocythemia, Essential; 38 are open to participants now.
Browse Thrombocythemia, Essential studies →7 of the 37 studies in Thrombocythemia, Essential with a site in France are open now. Recruiting first, the newest first:
Incyte Corporation · Sites in France, United States, Australia and 19 more countries
Ages 18+
Incyte Corporation · Sites in France, United States, Australia and 8 more countries
Ages 18+
University Hospital, Angers · Sites in France
Ages 18+
University Hospital, Brest · Sites in France
Ages 18+
University Hospital, Angers · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 34 Thrombocythemia, Essential studies recruiting now, 30 (88%) set no upper age limit and 3 (9%) stop at 75 or younger; 5 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 12 · Phase 4 1
First in 1999; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is close to the median of 52 across 168 interventional studies indexed under Thrombocythemia, Essential.
Median enrollment 160 across the 27 interventional studies, 295 across the 8 observational. Of the 24 that completed or were terminated, 10 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 37 have an industry lead sponsor. The 10 most frequent:
Step Pharma, SAS is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Step Pharma, SAS has 1 study filed under Thrombocythemia, Essential — fewer than ten, so there is no comparison to draw.
6 of the studies in Thrombocythemia, Essential with a site in France that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05198960Phase 3University Hospital, BrestAVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms | 2027-07-13 |
| NCT06079879Phase 3Merck Sharp & Dohme LLCA Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) | 2027-07-14 |
| NCT06456346Phase 3Merck Sharp & Dohme LLCBomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) | 2027-09-28 |
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT04942080University Hospital, AngersInterest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI) | 2027-04-28 |
Add all 6 to your calendar (.ics) → With an account.
Among the 37 studies in Thrombocythemia, Essential with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if the drug STP938 works to treat adults with high risk essential thrombocythaemia (ET) who are resistant to, or intolerant of, hydroxycarbamide (also known as hydroxyurea) therapy. The trial will also learn about the safety of STP938. The main questions the trial aims to answer are:
Participants will:
The aim of the study is to assess a new drug called STP938 for the treatment of essential thrombocythaemia (ET). The study with assess how effective STP938 in treating ET, and also assess any side effects of taking the drug. The study will enrol individuals with high risk ET who require treatment to lower their platelet count. Individuals enrolling on the study will have already tried treatment with hydroxycarbamide (also known as hydroxyurea) but are in need of a different treatment as hydroxycarbamide either did not control the platelet count or produced unwanted side effects.
STP938 is a new class of drug that inhibits the enzyme cytidine triphosphate synthase 1 (CTPS1). Inhibition of CTPS1 is a novel way of lowering the platelet count. This study is a phase 1b, open-label, multicentre trial. Participants will receive STP938 capsules every day, in cycles of 28 days, for approximately 12 months. Participants may continue to receive study drug for a longer period, so long as it is controlling the platelet count and not causing side effects. During the study, participants will visit the study site about 26 times (2 times per cycle) over an estimated 12 months. Once the treatment is complete, safety follow-up visit(s) will occur to make sure the participant is not experiencing any adverse effects. The following study procedures will be performed: (a) physical examinations (b) ECGs (c) blood tests, (d) urine tests (e) CT/MRI scans (f) bone marrow biopsies (g) drug administration (h) study drug blood level tests and (i) gene testing.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjustable dose levels with STP938 administered as oral therapy
Drug: STP938
At enrolment all patients will be assigned to a single dose level of STP938 for 4 weeks. After 4 weeks the dose level may be adjusted as needed by the Investigator.
Clinical Efficacy
Complete and partial response rates per European LeukemiaNet criteria
Time frame: Through study completion, an average of 12 months
Safety and Tolerability
Toxicity profile based on National Cancer Institute Common Terminology Criteria for Adverse Events
Time frame: Through study completion, an average of 12 months
Durability of Response to STP938
Time from achieving response to loss of response
Time frame: Through study completion, an average of 12 months
Impact of STP938 on Disease-Related Complications
Prevalence of haemorrhagic complications, thromboembolic events and disease transformation.
Time frame: Through study completion, an average of 12 months
Patient Reported Outcomes and Symptom Burden
Myeloproliferative Neoplasm Symptom Assessment Form (18 item). Minimum value is zero (0); the maximum value is 180. A score of zero equates to absence of symptoms, higher scores equate to worse outcome.
Time frame: Through study completion, an average of 12 months
Molecular Response
Change in Variant Allele Fraction: For known ET-associated mutations.
Time frame: Through study completion, an average of 12 months
Bone Marrow Histology
Changes in Histological Appearances
Time frame: Screening and Cycle 12 (each cycle is 28 days)
Spleen Volume
Change in Spleen Volume: Measured by MRI or CT scan.
Time frame: Through study completion, an average of 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Jun 2028, 36 months after the start.
Of 27 phase 2 interventional studies under Thrombocythemia, Essential, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 141. This study's planned 36 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dencatistat